Defined Flanking Spacers and Enhanced Proteolysis Is Essential for Eradication of Established Tumors by an Epitope String DNA Vaccine

Markwin P. Velders(Loyola University Chicago), W. Martin Kast(University of Southern California), Amira G. Elmishad(Loyola University Chicago), Sanne Weijzen(Loyola University Chicago), Richard B. Ciccarelli(Pearl River Community College), Mererid Evans(Velindre NHS Trust), Terry J. Higgins(Pearl River Community College), Gretchen L. Eiben(Loyola University Chicago), Stephen Man(Cardiff University), Larry Smith(Vical (United States)), Peter‐M. Kloetzel(Cal Poly Humboldt)
The Journal of Immunology
May 1, 2001
10.4049/jimmunol.166.9.5366
Cited by 187

Related Papers

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
|Nature Medicine|1995|1.1k
Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial
|The Lancet|2018|1k
The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes.
|The Journal of Immunology|1994|851
Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells
|European Journal of Immunology|1993|840